Jeffrey J. Molldrem, MD
(Co-founder of The Vaccine Company)
Professor of Medicine
Section Chief, Transplant Immunology
U.T. M.D. Anderson Cancer Center
Biography Coming Soon.
Prof. Molldrem’s University Website can be found here
Robert S. Negrin, MD
Professor of Medicine
Director, Blood and Marrow Transplant Program
Chief, Division of Blood and Marrow Transplantation
Stanford University School of Medicine
President, International Society for Cellular Therapy
Robert S. Negrin is a Professor of Medicine at Stanford University. He received his undergraduate degree from the University of California at Berkeley and his M.D. from Harvard Medical School. He performed his internship, residency and fellowship in Hematology at Stanford University. He joined the faculty at Stanford University in 1990 and was promoted to Associate Professor in 1997 and full professor in 2004. He has served as the President of the International Society of Cellular Therapy and the American Society of Blood and Marrow Transplantation. His research interests involve characterizing graft-versus-host and graft-versus-tumor reactions and developing cell-based therapeutics for the treatment of malignancies and other disorders. He is currently the Director of the Bone Marrow Transplant Program at Stanford University and Medical Director for the Stanford Cell Therapeutics Laboratory.
Ronald Levy, MD
Professor of Medicine and Chief, Division of Oncology
Stanford University School of Medicine
Dr. Ronald Levy's landmark research on the basic immuno-biology of lymphocytes and on monoclonal antibodies led to the development of rituximab, a widely successful treatment for B-cell lymphoma. Dr. Levy continues to study the mechanism of lymphoma initiation and progression to develop new monoclonal and vaccine therapies for this disease. Dr. Levy has received numerous honors and awards, including the Damashek Prize from the American Society of Hematology in 2004, the Jeffrey A. Gottlieb Memorial Award from the M.D. Anderson Cancer Center in 2003, the Evelyn Hoffman Memorial Award from the Lymphoma Research Foundation of America in 2001 and the Medal of Honor from the American Cancer Society in 2000.
Kenneth A. Foon, M.D.
The University of Pittsburgh Cancer Institute,
Division of Hematology-Oncology Pittsburgh, PA
Dr. Foon is the Director of Clinical Investigations and the Co-Director of the Biological Therapeutics and Hematologic Malignancies Program at the University of Pittsburgh Cancer Institute and is a Professor of Medicine at the School of Medicine. Dr. Foon is former Director of the Markey Cancer Center at the University of Kentucky and the Barrett Cancer Center at the University of Cincinnati. Dr. Foon has served on the editorial boards of sixteen scientific journals and has over 300 publications on his own work. He earned his medical degree from Wayne State University and was a fellow in Hematology and Oncology at the University of California, Los Angeles and trained in Immunology at the National Institutes of Health.
Victor Hoffbrand, MD
Honorary Consultant and
Emeritus Professor of Haematology at
Royal Free Hospital, U.K.
Victor Hoffbrand was Professor of Haematology and Head of Department at the Royal Free Hospital School of Medicine and Head of one of the largest Haematology Departments in the U.K. from 1974 until 1996. Since 1996 he has continued to work at the Royal Free Hospital as Honorary Consultant and Emeritus Professor of Haematology. He is a Fellow of the Royal Colleges of Physicians of London and Edinburgh and of the Royal College of Pathologists, a past President of the British Society of Haematology, Chairman of the Intercollegiate Committee of Haematology, and Chairman of the Editorial Board of the British Journal of Haematology. His research has been mainly into clinical, biochemical, and molecular aspects of leukaemia and lymphomas. Earlier research was in the field of megaloblastic anaemia and he has performed major research in iron chelation therapy, having pioneered the first orally effective iron chelating drug. He has written over 700 original articles, chapters or reviews within the field of haematology. Victor Hoffbrand has written two standard undergraduate textbooks of haematology, Essential Haematology (5th Edition 2006), and Haematology at a Glance (2nd Edition 2005) and a Clinical Atlas of Haematology (3rd Edition 2000). He is principal Editor of the standard British Textbook of Haematology, Postgraduate Haematology (5th Edition 2005).
(Co-founder of The Vaccine Company)
Professor of Medicine
Section Chief, Transplant Immunology
U.T. M.D. Anderson Cancer Center
Biography Coming Soon.
Prof. Molldrem’s University Website can be found here
Robert S. Negrin, MD
Professor of Medicine
Director, Blood and Marrow Transplant Program
Chief, Division of Blood and Marrow Transplantation
Stanford University School of Medicine
President, International Society for Cellular Therapy
Robert S. Negrin is a Professor of Medicine at Stanford University. He received his undergraduate degree from the University of California at Berkeley and his M.D. from Harvard Medical School. He performed his internship, residency and fellowship in Hematology at Stanford University. He joined the faculty at Stanford University in 1990 and was promoted to Associate Professor in 1997 and full professor in 2004. He has served as the President of the International Society of Cellular Therapy and the American Society of Blood and Marrow Transplantation. His research interests involve characterizing graft-versus-host and graft-versus-tumor reactions and developing cell-based therapeutics for the treatment of malignancies and other disorders. He is currently the Director of the Bone Marrow Transplant Program at Stanford University and Medical Director for the Stanford Cell Therapeutics Laboratory.
Ronald Levy, MD
Professor of Medicine and Chief, Division of Oncology
Stanford University School of Medicine
Dr. Ronald Levy's landmark research on the basic immuno-biology of lymphocytes and on monoclonal antibodies led to the development of rituximab, a widely successful treatment for B-cell lymphoma. Dr. Levy continues to study the mechanism of lymphoma initiation and progression to develop new monoclonal and vaccine therapies for this disease. Dr. Levy has received numerous honors and awards, including the Damashek Prize from the American Society of Hematology in 2004, the Jeffrey A. Gottlieb Memorial Award from the M.D. Anderson Cancer Center in 2003, the Evelyn Hoffman Memorial Award from the Lymphoma Research Foundation of America in 2001 and the Medal of Honor from the American Cancer Society in 2000.
Kenneth A. Foon, M.D.
The University of Pittsburgh Cancer Institute,
Division of Hematology-Oncology Pittsburgh, PA
Dr. Foon is the Director of Clinical Investigations and the Co-Director of the Biological Therapeutics and Hematologic Malignancies Program at the University of Pittsburgh Cancer Institute and is a Professor of Medicine at the School of Medicine. Dr. Foon is former Director of the Markey Cancer Center at the University of Kentucky and the Barrett Cancer Center at the University of Cincinnati. Dr. Foon has served on the editorial boards of sixteen scientific journals and has over 300 publications on his own work. He earned his medical degree from Wayne State University and was a fellow in Hematology and Oncology at the University of California, Los Angeles and trained in Immunology at the National Institutes of Health.
Victor Hoffbrand, MD
Honorary Consultant and
Emeritus Professor of Haematology at
Royal Free Hospital, U.K.
Victor Hoffbrand was Professor of Haematology and Head of Department at the Royal Free Hospital School of Medicine and Head of one of the largest Haematology Departments in the U.K. from 1974 until 1996. Since 1996 he has continued to work at the Royal Free Hospital as Honorary Consultant and Emeritus Professor of Haematology. He is a Fellow of the Royal Colleges of Physicians of London and Edinburgh and of the Royal College of Pathologists, a past President of the British Society of Haematology, Chairman of the Intercollegiate Committee of Haematology, and Chairman of the Editorial Board of the British Journal of Haematology. His research has been mainly into clinical, biochemical, and molecular aspects of leukaemia and lymphomas. Earlier research was in the field of megaloblastic anaemia and he has performed major research in iron chelation therapy, having pioneered the first orally effective iron chelating drug. He has written over 700 original articles, chapters or reviews within the field of haematology. Victor Hoffbrand has written two standard undergraduate textbooks of haematology, Essential Haematology (5th Edition 2006), and Haematology at a Glance (2nd Edition 2005) and a Clinical Atlas of Haematology (3rd Edition 2000). He is principal Editor of the standard British Textbook of Haematology, Postgraduate Haematology (5th Edition 2005).
